GlassScriptPhysician profile
Suleiman Daifallah
NPI 1982897682
$7,959.96
in general payments reported to CMS, 2019-2025
32 companies · $1,388 in 2025
The $1,388 reported for 2025 was more than what 85% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $811 · 2020: $1,067 · 2021: $1,079 · 2022: $1,152 · 2023: $1,085 · 2024: $1,377 · 2025: $1,388.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,851.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,850.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,278.67 | 2019-2025 | Farxiga, Lokelma, Evusheld |
| Calliditas Therapeutics US INC. | $1,007.44 | 2022-2025 | Tarpeyo |
| Bayer Healthcare Pharmaceuticals INC. | $915.19 | 2021-2025 | |
| Travere Therapeutics, INC. | $573.02 | 2019-2025 | |
| Amgen INC. | $520.94 | 2019-2025 | Krystexxa, Tavneos |
| Opko Pharmaceuticals, LLC | $409.20 | 2019-2024 | Rayaldee |
| Vifor Pharma, INC. | $368.74 | 2019-2025 | Veltassa, Korsuva |
| Mallinckrodt Hospital Products INC. | $361.79 | 2020-2025 | Acthar |
| Akebia Therapeutics INC | $355.56 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $334.64 | 2023-2025 | |
| Glaxosmithkline, LLC. | $269.81 | 2021-2025 | Benlysta, Arexvy |
| Fresenius USA Marketing, INC. | $226.28 | 2020-2025 | Velphoro, Velphoro |
| Mallinckrodt Enterprises LLC | $169.72 | 2019 | |
| Ani Pharmaceuticals, INC. | $167.96 | 2022-2025 | Purified Cortrophin Gel |
| Horizon Therapeutics Plc | $160.05 | 2019-2023 | Krystexxa |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inari Medical, INC. | $150.73 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Daiichi Sankyo INC. | $106.26 | 2019-2024 | Injectafer |
| Otsuka America Pharmaceutical, INC. | $97.87 | 2019-2025 | Jynarque |
| Novo Nordisk INC | $91.74 | 2023-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.26 | 2023-2024 | Jardiance |
| Ascendis Pharma Endocrinology INC | $59.85 | 2025 | Yorvipath |
| Medtronic, INC. | $39.16 | 2022 | |
| Ardelyx, INC. | $34.35 | 2024-2025 | Ibsrela |
| Shire North American Group INC | $27.91 | 2019 | |
| Alnylam Pharmaceuticals INC. | $24.06 | 2025 | Givlaari |
| Genzyme Corporation | $22.58 | 2022 | |
| Scpharmaceuticals INC. | $22.37 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.64 | 2023 | Gattex |
| Bard Peripheral Vascular, INC. | $19.59 | 2020 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $19.09 | 2022 | |
| Shield Therapeutics INC | $13.89 | 2024 | |
| Aurinia Pharma U.S., INC. | $12.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suleiman Daifallah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.